The Vanguard Group 13D and 13G filings for Alnylam Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-04-07 11:51 am Purchase | 2025-03-31 | 13G | Alnylam Pharmaceuticals, Inc. ALNY | The Vanguard Group | 13,056,605 10.030% | 1,112,710 (+9.32%) | Filing |
| 2024-02-13 4:59 pm Purchase | 2023-12-29 | 13G | Alnylam Pharmaceuticals, Inc. ALNY | The Vanguard Group | 11,943,895 9.520% | 436,779 (+3.80%) | Filing |
| 2023-02-09 11:07 am Purchase | 2022-12-30 | 13G | Alnylam Pharmaceuticals, Inc. ALNY | The Vanguard Group | 11,507,116 9.350% | 804,345 (+7.52%) | Filing |
| 2022-02-09 3:24 pm Purchase | 2021-12-31 | 13G | Alnylam Pharmaceuticals, Inc. ALNY | The Vanguard Group | 10,702,771 8.950% | 176,347 (+1.68%) | Filing |
| 2021-02-10 10:30 am Purchase | 2020-12-31 | 13G | Alnylam Pharmaceuticals, Inc. ALNY | The Vanguard Group | 10,526,424 9.060% | 238,952 (+2.32%) | Filing |